X

Drug Profile

Somatropin inhaled - Eli Lilly and Company/Alkermes

Alternative Names: AIR^® hGH; AIR^® human growth hormone; AIR^® somatropin

Latest Information Update: 24 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alkermes; Eli Lilly and Company
Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
Mechanism of Action Human growth hormone replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Somatotropin deficiency

Most Recent Events

24 Mar 2009 Discontinued - Phase-I for Somatotropin deficiency in USA (Inhalation)
22 May 2006 This compound is still in active development
04 Jul 2005 Data presented at the 87th Annual Meeting of the Endocrine Society (ENDO-2005) have been added to the adverse events and pharmacokinetics sections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com